Transitional Cell Carcinoma — Trials

Transitional Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

734 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 253
Recruiting: 125
Ph III recruiting: 17
Growth YoY: +47.5%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 44%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (119)

clinicaltrialsPublishedShowing 51–55 of 55 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02944357	Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery	withdrawn	N/A	0	Mayo ClinicOTHER	1	Nov 17, 2017	clinicaltrials
NCT03138824	Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC	unknown	N/A	100	Mansoura UniversityOTHER	1	May 23, 2017	clinicaltrials